There’s no question that some of the biggest moves in advanced healthcare technology today involve the use of a patient’s own cells, from attacking various diseases to the rebuilding of aged or damaged tissues. In the case of Regenicin, Inc., a New Jersey based biotechnology company, it’s all about the development of regenerative cell therapies to restore the health of damaged tissues. The company is currently working on a breakthrough technology that uses a patient’s own skin cells to generate living tissue-engineered skin for the treatment of burns and wounds. It represents a huge step for the thousands of severe burn cases occurring every year, promising less scaring, fewer infections, and faster healing.
Heading the effort is the Regenicin management team, each with an expertise in a particular aspect of the medical field.
• Randall McCoy (Chairman, CEO) has 37 years of healthcare industry experience, at both the scientific and executive levels, and has assisted small and large pharmaceutical and device companies in the addressing of FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products to the U.S. and world markets, and himself holds over 30 U.S. and international patents. His previous employment includes George Washington University, Temple University Medical School, and RCA/SRI International (Director of Life Sciences and Electronic Displays).
• John Weber (Interim CFO) served many years with Fujifilm Medical Systems USA, rising to Executive Vice President, the highest ranked American corporate officer, until his departure in 2009. During his time with the company, he spearheaded its transition from a film distributor to a digital medical informatics company, helping profitably manage the company’s growth from an employee base of only 75 to well over 1,000. Prior to this, he served as CFO and Corporate Controller for a division of Cadbury Schweppes.
• Chris Hadsall (COO), a 10-year veteran of the U.S. Marine Corps, brings experience as founder and Executive Director of the VET Foundation, dedicated to helping injured veterans transition to civilian life. He designed, developed, and implemented a holistic reintegration program, in addition to being responsible for fund raising and the financial health of the organization. Prior to that, he worked as Regional Manager for Professional Staffing ABTS, guiding day-to-day operations and business development for a major expansion.
• Richard Koeninger (Director of Regulatory Affairs) offers 29 years of experience with the FDA, where he worked in Field Investigations and as a Drug and Device Specialist, and overseas as the Associate Director of Emergency and Investigational Operations, and had the distinction of being the International FDA Expert for Drugs and Devices. He has served on Institutional Review Boards for clinical trials, and has conducted FDA pre-approval investigations.
• Lauri-Ann Hahn (Director of Clinical Trials) is experienced in all areas of clinical research, from planning and conducting studies, to FDA clinical report submissions. She served as Associate Director of Clinical Trials and Sr. Project Manager for Lonza Walkersville, Inc., where she gained direct experience working with Cultured Skin Substitute. She has also worked at the National Institutes of Health, and was Head of Clinical Research at the University of Pittsburgh Department of Urology.
For additional information, visit the company’s website at www.Regenicin.com
Let us hear your thoughts: Regenicin, Inc. Message Board